Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in Advanced Renal Cell Carcinoma
NCT00096525Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2004
- Primary completion
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in renal cell carcinoma (RCC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Best Response and Time to Disease Progression. Started Jul 2004; status: completed.
02
Drugs
lenalidomide
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00096525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00096525.